Skip to main content
. Author manuscript; available in PMC: 2009 Oct 26.
Published in final edited form as: Ann Neurol. 2008 Jun;63(6):697–708. doi: 10.1002/ana.21420

Fig 4.

Fig 4

Characterization of PrP in PSPr A: On conventional immunoblots, PK-resistant PrP is undetectable in non-prion disease controls (non-PrD) and the present subjects (PSPr), while it is prominent in sCJD. B: PK-resistant PrP from non-PrD and PSPr is not detectable even after treatment with very low PK concentrations but only in sCJD control when probed with the mAb 3F4. C: Sub-cortical regions of three PSPr cases treated with PK at 50 µg/ml prior to Western blot analysis with 3F4 showed various amounts of PK-resistant PrP in three PSPr cases. T1: PrPr type 1 control; T2: PrPr type 2 control; SN: substantia nigra; Pu: putamen; and Th: thalamus. Samples from temporal cortex (Tc) were used as controls. BH: brain homogenate. D: When the same samples used in B are probed with 1E4, moderately PK-resistant PrP fragments forming a ladder are observed. A, B and D tissues are from the frontal cortex.